| Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT03127215) | National Center for Tumor Diseases, Heidelberg | 2018-10-25 |
| Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer (NCT02577588) | National Center for Tumor Diseases, Heidelberg | 2016-05-01 |
| Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NCT02454634) | National Center for Tumor Diseases, Heidelberg | 2015-06-01 |
| CCR5-blockade in Metastatic Colorectal Cancer (NCT01736813) | National Center for Tumor Diseases, Heidelberg | 2012-11-01 |
| Vorinostat in Children (NCT01422499) | National Center for Tumor Diseases, Heidelberg | 2012-03-01 |
| Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer (NCT01443377) | National Center for Tumor Diseases, Heidelberg | 2011-07-01 |
| Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (NCT01693159) | National Center for Tumor Diseases, Heidelberg | 2011-05-01 |
| Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (NCT01216696) | National Center for Tumor Diseases, Heidelberg | 2010-11-01 |
| Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (NCT01271322) | National Center for Tumor Diseases, Heidelberg | 2010-10-01 |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (NCT01145404) | National Center for Tumor Diseases, Heidelberg | 2010-06-01 |
| Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer (NCT01362582) | National Center for Tumor Diseases, Heidelberg | 2010-03-01 |
| Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (NCT01126866) | National Center for Tumor Diseases, Heidelberg | 2009-06-01 |